The abstract is read at the publisher; the summary is JClub's.
EU-PEARL consensus guidance recommends early regulator engagement and careful IRP design for TB adaptive platform trials, emphasizing decision rules and surrogate markers to support regulatory acceptance.
- Why it matters: TB remains highly lethal despite a growing drug pipeline, yet there is limited progress in treatment improvement. Clear, evidence-based regulatory guidance for integrated research platforms in TB is lacking.
- What they did: A multidisciplinary Task Force reviewed regulatory pathways for IRPs with a focus on TB, then discussed gaps and needs in two consultations to produce consensus recommendations. The guidance highlights early contact with national regulators and supranational bodies, plus surrogate marker development and clear phase-transition decision rules.
- The result: The recommendations suggest that improved design, data leverage, and stratification can strengthen scientific validity and enhance regulatory acceptability, supporting more impactful global TB treatment strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.